GAMMA Investing LLC Buys 6,215 Shares of Haleon plc (NYSE:HLN)

GAMMA Investing LLC raised its position in shares of Haleon plc (NYSE:HLN) by 41.3% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 21,258 shares of the company’s stock after acquiring an additional 6,215 shares during the quarter. GAMMA Investing LLC’s holdings in Haleon were worth $203,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Fortitude Family Office LLC purchased a new position in shares of Haleon in the 3rd quarter valued at approximately $28,000. Versant Capital Management Inc lifted its position in Haleon by 2,029.1% during the fourth quarter. Versant Capital Management Inc now owns 3,513 shares of the company’s stock valued at $34,000 after buying an additional 3,348 shares during the period. Toronto Dominion Bank grew its position in shares of Haleon by 3,470.0% in the 3rd quarter. Toronto Dominion Bank now owns 3,570 shares of the company’s stock worth $38,000 after buying an additional 3,470 shares during the period. Prospera Private Wealth LLC bought a new position in shares of Haleon in the 3rd quarter worth about $57,000. Finally, BOKF NA lifted its position in Haleon by 68.8% during the 2nd quarter. BOKF NA now owns 6,972 shares of the company’s stock valued at $58,000 after acquiring an additional 2,842 shares during the period. Hedge funds and other institutional investors own 6.67% of the company’s stock.

Haleon Stock Performance

Shares of HLN stock opened at $9.47 on Wednesday. The company has a market capitalization of $42.87 billion, a price-to-earnings ratio of 27.85, a price-to-earnings-growth ratio of 2.95 and a beta of 0.29. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.58 and a current ratio of 0.84. Haleon plc has a one year low of $7.89 and a one year high of $10.80. The company’s 50-day moving average is $9.62 and its 200 day moving average is $9.67.

Analyst Ratings Changes

A number of equities research analysts have weighed in on HLN shares. Morgan Stanley upped their price objective on shares of Haleon from $9.90 to $10.95 and gave the stock an “overweight” rating in a report on Friday, September 20th. UBS Group upgraded Haleon to a “strong-buy” rating in a research note on Tuesday, October 1st. One research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Haleon presently has a consensus rating of “Buy” and an average target price of $10.95.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.